Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Explore clinical trials studying Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. Study availability and eligibility vary by location and protocol.

2 public trials 1 recruiting study

Refine in advanced search Browse all conditions

Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma trial results

Recruiting

A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

NCT07327229

Conditions: Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Locations: Anhui Provincial Hospital Hefei, Anhui, China

The First Affiliated Hospital of Anhui Medical University Hefei, Anhui, China

Beijing Cancer hospital Beijing, Beijing Municipality, China

Fujian Provincial Cnacer Hospital Fuzhou, Fujian, China

View all 30 locations

View Trial Details

Active, Not Recruiting

A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)

NCT06238843

Conditions: Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Locations: The First Affiliated Hospital of Bengbu Medical University Bengbu, Anhui, China

Anhui Provincial Hospital Hefei, Anhui, China

The First Affiliated Hospital of USTC /Anhui Provincial Hospital Hefei, Anhui, China

The First Affiliated Hospital of Anhui Medical University Hefei, Anhui, China

View all 95 locations

View Trial Details